Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/9801
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae |
Author: | Black, P. Blasi, F. Jenkins, C. Scicchitano, R. Mills, G. Rubinfeld, A. Ruffin, R. Mullins, P. Dangain, J. Cooper, B. David, D. Allegra, L. |
Citation: | American Journal of Respiratory and Critical Care Medicine, 2001; 164(4):536-541 |
Publisher: | Amer Lung Assoc |
Issue Date: | 2001 |
ISSN: | 1073-449X 1535-4970 |
Statement of Responsibility: | Peter N. Black, Francesco Blasi, Christine R. Jenkins, Raffaele Scicchitano, Graham D. Mills, Abraham R. Rubinfeld, Richard E. Ruffin, Peter R. Mullins, Josette Dangain, Bruce C. Cooper, Denise Bem David, And Luigi Allegra |
Abstract: | Chlamydia pneumoniae and the severity of asthma, and uncontrolled observations have suggested that treatment with antibiotics active against C. pneumoniae leads to an improvement in asthma control. We studied the effect of roxithromycin in subjects with asthma and immunoglobulin G (IgG) antibodies to C. pneumoniae > 1:64 and/or IgA antibodies > 1:16. A total of 232 subjects, from Australia, New Zealand, Italy, or Argentina, were randomized to 6 wk of treatment with roxithromycin 150 mg twice a day or placebo. At the end of 6 wk, the increase from baseline in evening peak expiratory flow (PEF) was 15 L/min with roxithromycin and 3 L/min with placebo (p 0.02). With morning PEF, the increase was 14 L/min with roxithromycin and 8 L/min with placebo (NS). In the Australasian population, the increase in morning PEF was 18 L/min and 4 L/min, respectively (p = 0.04). At 3 mo and 6 mo after the end of treatment, differences between the two groups were smaller and not significant. Six weeks of treatment with roxithromycin led to improvements in asthma control but the benefit was not sustained. Further studies are necessary to determine whether the lack of sustained benefit is due to failure to eradicate C. pneumoniae. |
Keywords: | Humans Chlamydophila pneumoniae Chlamydophila Infections Pneumonia, Bacterial Asthma Chronic Disease Roxithromycin Immunoglobulin G Antibodies, Bacterial Anti-Bacterial Agents Peak Expiratory Flow Rate Forced Expiratory Volume Treatment Outcome Severity of Illness Index Follow-Up Studies Double-Blind Method Time Factors Adult Middle Aged Female Male |
Description: | Copyright © 2001 American Thoracic Society |
DOI: | 10.1164/ajrccm.164.4.2011040 |
Published version: | http://dx.doi.org/10.1164/ajrccm.164.4.2011040 |
Appears in Collections: | Aurora harvest 4 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.